In further support of the importance of pyruvate metabolism in affecting PD pathology, Mallet et al. (2022) have recently demonstrated that treatment with MSDC-0160 treatment improved motor behavior, decreased dopaminergic denervation, and reduced mTOR activity and neuroinflammation in the unilateral 6-OHDA rat model of PD. Here, MTOR is linked to Parkinson disease.